Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corvus Pharmaceuticals reports Q4 loss, highlights CPI-818 potential and challenges

Corvus Pharmaceuticals showcased a mixed financial performance with a focus on managing cash burn rate and extending cash runway.
The company's strength lies in the potential of CPI-818 in various indications and the identification of a patient selection biomarker.
Challenges include cash management, regulatory hurdles in upcoming trials, and the need for clarity on biomarker validation.
Opportunities abound in market expansion, clinical development acceleration, and strategic initiatives for growth and value creation.

Corvus Pharmaceuticals reports Q1 progress with CPI-818 advancements

Corvus Pharmaceuticals reported financial improvements and progress in CPI-818 development.
Partnerships and upcoming trials indicate a promising future for the company.
Challenges lie in addressing analyst queries and ensuring trial success and data presentation.

Corvus Pharmaceuticals reports Q2 progress in cancer drug trials

Corvus Pharmaceuticals reported improved financials with reduced expenses and strategic stock sales, while advancing key drug trials in cancer treatment.
The company's focus on innovative drug development in cancer immunotherapy presents opportunities for growth and partnerships.
Challenges lie in managing expenses, conducting rigorous clinical evaluations, and balancing financial decisions with strategic priorities.

Corvus Pharmaceuticals reports Q3 progress in oncology and immune diseases

Corvus Pharmaceuticals reported a net loss of $6 million in Q3 2023 but showcased progress on soquelitinib and potential in ITK inhibition for immune diseases.
The company's financial overview and upcoming milestones indicate a strategic focus on advancing pipeline candidates and exploring partnerships.
While facing challenges in managing expenses and balancing resources, Corvus Pharmaceuticals has opportunities to drive growth through positive trial results and strategic partnerships.

Corvus Pharmaceuticals advances pipeline with promising therapies and partnerships

Corvus Pharmaceuticals showcased financial improvements and progress in their pipeline programs during Q4 2023 earnings call.
The company's focus on ITK inhibition and orphan drug designation for soquelitinib highlight their commitment to innovative therapies.
While facing cash challenges, Corvus is actively seeking partnerships and advancing trials to capitalize on commercial and medical opportunities.

Corvus Pharmaceuticals reports improved financials and promising clinical advancements

Corvus Pharmaceuticals demonstrated improved financials and strong clinical progress in Q1 2024, supported by recent financing.
The company's focus on Soquelitinib and ciforadenant presents promising opportunities for growth and advancement in the oncology space.
Challenges lie in operational scalability, trial design complexities, and the need for clear patient criteria and efficacy benchmarks.

Corvus Pharmaceuticals reports strong Q2 performance and advances key drugs

Corvus Pharmaceuticals demonstrated financial stability and clinical progress in Q2 2024, with a strong cash position and promising pipeline.
The company's focus on selective ITK inhibition for immune diseases and cancer shows commitment to innovative therapies and addressing unmet medical needs.
While facing challenges in trial expectations and resource allocation, Corvus Pharmaceuticals has opportunities for growth through portfolio diversification and milestone achievements.
Overall, Corvus Pharmaceuticals is well-positioned to capitalize on its strengths, navigate challenges, and seize opportunities in the biopharmaceutical market.

Corvus Pharmaceuticals reports Q3 losses but advances key cancer treatments

Corvus Pharmaceuticals' Q3 performance reflects increased R&D expenses but a secure financial position with available cash and potential additional funds.
The company's strengths lie in its strong pipeline, progress in key trials, and a stable financial runway into 2026 for upcoming milestones.
Challenges include addressing questions on trial specifics, competitive landscape scrutiny, and operational complexities in trial management.
Opportunities exist in advancing innovative treatments, exploring market potential, and addressing immunotherapy resistance in cancer therapy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Camber Energy

Reed's

These penny stocks shot up today, are they worth watching or not? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 You Need to Know About

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for patients with unresectable, stage 3 non-small cell lung cancer.

What's Going On With Corvus Pharmaceuticals Stock Today?

Corvus Pharmaceuticals (CRVS) stock is rising higher on heavy trading volume Friday despite a lack of news from the company. The post 12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (CRVS) as Shares Rocket appeared first on InvestorPlace.

12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (CRVS) as Shares Rocket

The stock price of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) increased by over 50% pre-market. This is why it happened.

CRVS Stock: Why It Significantly Increased Today

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will participate in two upcoming investor conferences in September:

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021 Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)

BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Peabody Energy

Crestwood Equity Partners

CuriosityStream

Energy Transfer LP Unit

FuboTV

Genco Shipping & Trading

Helix Energy Solutions Group

H&R Block

Jewett-Cameron Trading

Karyopharm Therapeutics

Tenet Fintech Group Inc

Palantir Technologies

Amplify Junior Silver Miners ETF

Schlumberger

SPDR S&P 500 ETF Trust

TransGlobe Energy

At the mid-year mark, our contributors give updates on their picks.

SA Marketplace 2021 Top Idea Contest: Mid-Year Update

The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has discontinued its Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering infection and hospitalizations. The discontinuation is not related to any safety or efficacy issues, the company said in the press release.

Corvus Pulls Plug On Mupadolimab COVID-19 Program With Candidate Now Prioritized In Oncology

Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human papilloma virus) head and neck cancer

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET.

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the Company's ATM program established on March 9, 2020 through Jefferies LLC (“Jefferies”), acting as sales agent.

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

BURLINGAME, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2021.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Bumble

Fiserv

Anterix Inc

Decibel Therapeautics

Molecular Templates

NexImmune

Oncorus

Prothena

Talis Biomedical

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters' partial exercise of their option to purchase additional shares of common stock, at a price to the public of $3.50 per share. All shares in the offering were sold by Corvus, with gross proceeds to Corvus of $34.2 million and net proceeds of approximately $31.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

CollPlant Biotechnologies Ltd - ADR

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, for gross proceeds of $30.0 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus. All of the shares are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of common stock at the public offering price, less underwriting discounts and commissions.

Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition

Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS)

Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2

News for Corvus Pharmaceuticals Stock (CRVS)